342 related articles for article (PubMed ID: 34887643)
1. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
Makary MS; Ramsell S; Miller E; Beal EW; Dowell JD
World J Gastroenterol; 2021 Nov; 27(43):7462-7479. PubMed ID: 34887643
[TBL] [Abstract][Full Text] [Related]
2. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.
Makary MS; Khandpur U; Cloyd JM; Mumtaz K; Dowell JD
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32679897
[TBL] [Abstract][Full Text] [Related]
3. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
5. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
Poon RT; Fan ST; Tsang FH; Wong J
Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
[TBL] [Abstract][Full Text] [Related]
6. Update on Embolization Therapies for Hepatocellular Carcinoma.
Kishore S; Friedman T; Madoff DC
Curr Oncol Rep; 2017 Jun; 19(6):40. PubMed ID: 28421483
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
8. Metastatic disease to the liver: Locoregional therapy strategies and outcomes.
Zane KE; Cloyd JM; Mumtaz KS; Wadhwa V; Makary MS
World J Clin Oncol; 2021 Sep; 12(9):725-745. PubMed ID: 34631439
[TBL] [Abstract][Full Text] [Related]
9. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience.
Abdelfattah MR; Al-Sebayel M; Broering D; Alsuhaibani H
Transplant Proc; 2015 Mar; 47(2):408-11. PubMed ID: 25769582
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions.
Kumar Y; Sharma P; Bhatt N; Hooda K
Asian Pac J Cancer Prev; 2016; 17(2):473-8. PubMed ID: 26925630
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Lee EW; Khan S
Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
[TBL] [Abstract][Full Text] [Related]
12. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
13. Curative-Intent Therapies in Localized Hepatocellular Carcinoma.
O'Leary C; Mahler M; Soulen MC
Curr Treat Options Oncol; 2020 Mar; 21(4):31. PubMed ID: 32193784
[TBL] [Abstract][Full Text] [Related]
14. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
[TBL] [Abstract][Full Text] [Related]
15. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
16. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma.
Jazieh KA; Arabi M; Khankan AA
Saudi J Gastroenterol; 2014; 20(6):333-41. PubMed ID: 25434313
[TBL] [Abstract][Full Text] [Related]
17. Salvage locoregional therapies for recurrent hepatocellular carcinoma.
Criss CR; Makary MS
World J Gastroenterol; 2023 Jan; 29(3):413-424. PubMed ID: 36688022
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
